Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines.

Bai JX, Yan B, Zhao ZN, Xiao X, Qin WW, Zhang R, Jia LT, Meng YL, Jin BQ, Fan DM, Wang T, Yang AG.

Endocrinology. 2013 Feb;154(2):635-45. doi: 10.1210/en.2012-1607. Epub 2013 Jan 7.

PMID:
23295740
2.

MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.

Chen D, Huang J, Zhang K, Pan B, Chen J, De W, Wang R, Chen L.

Eur J Cancer. 2014 Nov;50(17):3050-67. doi: 10.1016/j.ejca.2014.09.008. Epub 2014 Oct 10.

PMID:
25310895
3.

Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma.

Castilla MÁ, Moreno-Bueno G, Romero-Pérez L, Van De Vijver K, Biscuola M, López-García MÁ, Prat J, Matías-Guiu X, Cano A, Oliva E, Palacios J.

J Pathol. 2011 Jan;223(1):72-80. doi: 10.1002/path.2802. Epub 2010 Oct 29.

PMID:
21125666
4.

MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.

Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu Q, Song E, Li J.

Oncogene. 2012 Jan 26;31(4):432-45. doi: 10.1038/onc.2011.263. Epub 2011 Jul 4.

PMID:
21725369
5.

MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1.

Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, Sakuragi N.

Mol Cancer. 2011 Aug 18;10:99. doi: 10.1186/1476-4598-10-99.

6.

Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.

Ward A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, Hielscher T, Wiemann S, Sahin Ö.

Oncogene. 2013 Feb 28;32(9):1173-82. doi: 10.1038/onc.2012.128. Epub 2012 Apr 16.

PMID:
22508479
7.

Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice.

Dardes RC, Bentrem D, O'Regan RM, Schafer JM, Jordan VC.

Clin Cancer Res. 2001 Dec;7(12):4149-55.

8.

MIR-99a and MIR-99b modulate TGF-β induced epithelial to mesenchymal plasticity in normal murine mammary gland cells.

Turcatel G, Rubin N, El-Hashash A, Warburton D.

PLoS One. 2012;7(1):e31032. doi: 10.1371/journal.pone.0031032. Epub 2012 Jan 27.

10.

MiRNA-200b represses transforming growth factor-β1-induced EMT and fibronectin expression in kidney proximal tubular cells.

Tang O, Chen XM, Shen S, Hahn M, Pollock CA.

Am J Physiol Renal Physiol. 2013 May 15;304(10):F1266-73. doi: 10.1152/ajprenal.00302.2012. Epub 2013 Feb 13.

11.

Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells.

Ren D, Wang M, Guo W, Huang S, Wang Z, Zhao X, Du H, Song L, Peng X.

Cell Tissue Res. 2014 Dec;358(3):763-78. doi: 10.1007/s00441-014-2001-y. Epub 2014 Oct 9.

PMID:
25296715
12.

SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer.

Liu L, Zhang J, Yang X, Fang C, Xu H, Xi X.

PLoS One. 2015 Sep 25;10(9):e0138515. doi: 10.1371/journal.pone.0138515. eCollection 2015.

13.

miR-205 promotes epithelial-mesenchymal transition by targeting AKT signaling in endometrial cancer cells.

Jin C, Liang R.

J Obstet Gynaecol Res. 2015 Oct;41(10):1653-60. doi: 10.1111/jog.12756.

PMID:
26446417
14.

Trastuzumab therapy for tamoxifen-stimulated endometrial cancer.

Osipo C, Meeke K, Liu H, Cheng D, Lim S, Weichel A, Jordan VC.

Cancer Res. 2005 Sep 15;65(18):8504-13.

15.

Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics.

Koutsaki M, Spandidos DA, Zaravinos A.

Cancer Lett. 2014 Sep 1;351(2):173-81. doi: 10.1016/j.canlet.2014.05.022. Epub 2014 Jun 18. Review.

PMID:
24952258
16.

miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer.

Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, Dornan D.

PLoS One. 2013 Jun 11;8(6):e66502. doi: 10.1371/journal.pone.0066502. Print 2013.

17.

The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.

Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, Maggiolini M.

Mol Endocrinol. 2006 Mar;20(3):631-46. Epub 2005 Oct 20.

PMID:
16239258
18.

MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.

Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K, Gemma A.

Mol Cancer Ther. 2014 Feb;13(2):444-53. doi: 10.1158/1535-7163.MCT-13-0448. Epub 2013 Nov 20.

19.

The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1).

Chen Z, Zhang D, Yue F, Zheng M, Kovacevic Z, Richardson DR.

J Biol Chem. 2012 May 18;287(21):17016-28. doi: 10.1074/jbc.M112.350470. Epub 2012 Mar 27.

20.

Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN.

Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y, Zhao L, Qu H, Fan Y, Wu C.

PLoS One. 2012;7(6):e39520. doi: 10.1371/journal.pone.0039520. Epub 2012 Jun 25.

Supplemental Content

Support Center